Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek, email him directly: email@example.com (mailto:firstname.lastname@example.org)
Who am I?
Consultant strategist providing competitive and market intelligence to investors in the biopharmaceutical industry ; founder of Qstat Consulting, a boutique strategic consulting firm specialized in competitive markets in Life Sciences industry [http://www.qstatconsulting.com]. In this role, I drive market and competitive intelligence research (primary & secondary) to enable investment strategies and translate findings into critical insights.
What do we offer?
Depending on the requested depth of analysis, we provide primary and secondary research for Key Intelligence Topics (KITs) and Key Intelligence Questions (KIQs).
Under a professional code of conduct, the consultant legally and ethically identify corporate information using a questionnaire technique.
We provide insights and detailed forecast of corporate strategies, which are essential for an investment decision making-process (e.g. the exact release date of trial data, any side-effects, safety or lack of efficacy to be further investigated, go-to-market plans, pricing structure, global regulatory and medical activities)
The secondary framework combines data about the company, drug(s) of interest (summary, patents and generics, regulatory, pre-marketing, preclinical and clinical activities, pricing, market target), marketing research, upcoming milestones, internal strengths and weaknesses, external opportunities and threats, competitive profile matrix (innovation, use of corporate assets, financial soundness, long-term investment, global competitiveness, acquisition, product diversification, product quality, marketing, R&D, patents...)
Primary and secondary data can be combined together to create a full-report, which confidential data are essential in the investment strategy.